The discovery of imatinib, a signal transduction inhibitor, towards the end of the last century revolutionized the treatment of Chronic Myelogenous Leukemia (CML)

The discovery of imatinib, a signal transduction inhibitor, towards the end of the last century revolutionized the treatment of Chronic Myelogenous Leukemia (CML). Excellent haematological response as well as cytogenetic response made imatinib the standard of care in CML. It is and belongs to the category of EGFR-tyrosine kinase inhibitors.

 

Indications:

  • Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)
  • Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy
  • Ph+ Acute Lymphoblastic Leukemia (ALL)
  • Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
  • Aggressive Systemic Mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown
  • Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and also if fusion kinase negative or unknown
  • Dermatofibrosarcoma Protuberans (DFSP)
  • Kit+ Gastrointestinal Stromal Tumors (GIST)
  • Adjuvant Treatment of GIST

 

Generic Name

Strength

Standard

Type

Packing

Pack Size

Imatinib

100mg

HIS

Capsules

Bottle

1x30s

Imatinib

400mg

HIS

Tablets

Strips

1x10s